Dr. Stephen Safe Lab
Cancer is the second leading cause of death in the United
States, and has a great impact on public health. Dr. Safe’s
laboratory studies cellular and molecular oncology. The
studies are focused on developing new mechanism based
anticancer agents that target the Ah receptor, the nuclear
receptors NR4A1, NR4A2 and NR4A3 and the Sp transcription factors.
Research is also focused on long non-coding RNAs (lncRNAs) and
their functions and on the roles of the Ah and NR4A receptors in
mediating ligand-induced responses in non-tumor tissues.
Our lab has characterized the role of several long non-coding
RNAs in cancer development, including HOTTIP, HOTAIR in pancreatic
cancer and those lncRNAs could be potential serum biomarkers and
therapeutic targets. We also discovered the role of specificity
protein transcription factors in cancer cells as non-oncogene
addiction genes. In addition, we also identified the anticancer
activity and its underlying mechanism of various small molecule
compounds, such as sulindac sulfide, metformin, omeprazole,
diindolylmethane analogs, phenethylisothiocyanate.